Top

Published in:

Open Access 01-12-2011 | Study protocol

A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: The AIO KRK 0110 Trial/ML22011 Trial

Authors: Clemens Giessen, Ludwig Fischer von Weikersthal, Axel Hinke, Sebastian Stintzing, Frank Kullmann, Ursula Vehling-Kaiser, Julia Mayerle, Markus Bangerter, Claudio Denzlinger, Markus Sieber, Christian Teschendorf, Jens Freiberg-Richter, Christoph Schulz, Dominik Paul Modest, Nicolas Moosmann, Philipp Aubele, Volker Heinemann

Published in: BMC Cancer | Issue 1/2011

Abstract

Background

Several randomized trials have indicated that combination chemotherapy applied in metastatic colorectal cancer (mCRC) does not significantly improve overall survival when compared to the sequential use of cytotoxic agents (CAIRO, MRC Focus, FFCD 2000-05). The present study investigates the question whether this statement holds true also for bevacizumab-based first-line treatment including escalation- and de-escalation strategies.

Methods/Design

The AIO KRK 0110/ML22011 trial is a two-arm, multicenter, open-label randomized phase III trial comparing the efficacy and safety of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in the first-line treatment of metastatic colorectal cancer. Patients with unresectable metastatic colorectal cancer, Eastern Cooperative Oncology Group (ECOG) performance status 0-1, will be assigned in a 1:1 ratio to receive either capecitabine 1250 mg/m² bid for 14d (d1-14) plus bevacizumab 7.5 mg/kg (d1) q3w (Arm A) or capecitabine 800 mg/m² BID for 14d (d1-14), irinotecan 200 mg/m² (d1) and bevacizumab 7.5 mg/kg (d1) q3w (Arm B). Patients included into this trial are required to consent to the analysis of tumour tissue and blood for translational investigations. In Arm A, treatment escalation from Cape-Bev to CAPIRI-Bev is recommended in case of progressive disease (PD). In Arm B, de-escalation from CAPIRI-Bev to Cape-Bev is possible after 6 months of treatment or in case of irinotecan-associated toxicity. Re-escalation to CAPIRI-Bev after PD is possible. The primary endpoint is time to failure of strategy (TFS). Secondary endpoints are overall response rate (ORR), overall survival, progression-free survival, safety and quality of life.

Conclusion

The AIO KRK 0110 trial is designed for patients with disseminated, but asymptomatic mCRC who are not potential candidates for surgical resection of metastasis. Two bevacizumab-based strategies are compared: one starting as single-agent chemotherapy (Cape-Bev) allowing escalation to CAPIRI-Bev and another starting with combination chemotherapy (CAPIRI-Bev) and allowing de-escalation to Cape-Bev and subsequent re-escalation if necessary.

Trial Registration

ClinicalTrials.gov Identifier NCT01249638

EudraCT-No.: 2009-013099-38

Available only for authorised users

Adam R, Haller DG, Poston G, Raoul J-L, Spano J-P, Tabernero J, Van Cutsem E: Toward optimized front-line therapeutic strategies in patients with metastatic colorectal cancer--an expert review from the International Congress on Anti-Cancer Treatment (ICACT) 2009. Annals of Oncology. 2010

Petrelli NJ, Abbruzzese J, Mansfield P, Minsky B: Hepatic resection: the last surgical frontier for colorectal cancer. J Clin Oncol. 2005, 23 (20): 4475-7.PubMed

Grothey A, Hedrick EE, Mass RD, Sarkar S, Suzuki S, Ramanathan RK, Hurwitz HI, Goldberg RM, Sargent DJ: Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107. J Clin Oncol. 2008, 26 (2): 183-9. 10.1200/JCO.2007.13.8099.CrossRefPubMed

Feliu J, Salut A, Safont M, Losa F, Garcia C, Bosch C, Escudero P, Lopez R, Bolanos M, Gonzalez-Baron M, ONCOPAZ group: First-line treatment with bevacizumab plus capecitabine for elderly patients with metastatic colorectal cancer: BECA trial. ASCO Meeting Abstracts. 2008, 26 (15_suppl): 15120-

Tebbutt NC, Wilson K, Gebski VJ, Cummins MM, Zannino D, van Hazel GA, Robinson B, Broad A, Ganju V, Ackland SP, Forgeson G, Cunningham D, Saunders MP, Stockler MR, Chua Y, Zalcberg JR, Simes RJ, Price TJ: Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. J Clin Oncol. 2010, 28 (19): 3191-8. 10.1200/JCO.2009.27.7723.CrossRefPubMed

Ducreux M, Adenis A, Mendiboure J, Francois E, Boucher E, Chauffert B, Ychou M, Pierga J, Montoto-Grillot C, Conroy T: Efficacy and safety of bevacizumab (BEV)-based combination regimens in patients with metastatic colorectal cancer (mCRC): Randomized phase II study of BEV + FOLFIRI versus BEV + XELIRI (FNCLCC ACCORD 13/0503 study). ASCO Meeting Abstracts. 2009, 27 (15S): 4086-

Reinacher-Schick AC, Kubicka S, Freier W, Arnold D, Dietrich G, Geissler M, Hegewisch-Becker S, Graeven U, Schmoll H, Schmiegel W: Activity of the combination of bevacizumab (Bev) with capecitabine/irinotecan (CapIri/Bev) or capecitabine/oxaliplatin (CapOx/Bev) in advanced colorectal cancer (ACRC): A randomized phase II study of the AIO Colorectal Study Group (AIO trial 0604). ASCO Meeting Abstracts. 2008, 26 (15_suppl): 4030-

Fuchs CS, Marshall J, Mitchell E, Wierzbicki R, Ganju V, Jeffery M, Schulz J, Richards D, Soufi-Mahjoubi R, Wang B, Barrueco J: Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol. 2007, 25 (30): 4779-86. 10.1200/JCO.2007.11.3357.CrossRefPubMed

Koopman M, Antonini NF, Douma J, Wals J, Honkoop AH, Erdkamp FL, de Jong RS, Rodenburg CJ, Vreugdenhil G, Loosveld OJ, van Bochove A, Sinnige HA, Creemers GJ, Tesselaar ME, Slee PH, Werter MJ, Mol L, Dalesio O, Punt CJ: Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet. 2007, 370 (9582): 135-42. 10.1016/S0140-6736(07)61086-1.CrossRefPubMed

10.

Rothenberg ML, Meropol NJ, Poplin EA, Van Cutsem E, Wadler S: Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. J Clin Oncol. 2001, 19 (18): 3801-7.PubMed

11.

Moosmann N, von Weikersthal LF, Vehling-Kaiser U, Stauch M, Hass HG, Dietzfelbinger H, Oruzio D, Klein S, Zellmann K, Decker T, Schulze M, Abenhardt W, Puchtler G, Kappauf H, Mittermuller J, Haberl C, Schalhorn A, Jung A, Stintzing S, Heinemann V: Cetuximab Plus Capecitabine and Irinotecan Compared With Cetuximab Plus Capecitabine and Oxaliplatin As First-Line Treatment for Patients With Metastatic Colorectal Cancer: AIO KRK-0104--A Randomized Trial of the German AIO CRC Study Group. J Clin Oncol. 2011

12.

Schmiegel W, Pox C, Reinacher-Schick A, Adler G, Arnold D, Fleig W, Folsch UR, Fruhmorgen P, Graeven U, Heinemann V, Hohenberger W, Holstege A, Junginger T, Kopp I, Kuhlbacher T, Porschen R, Propping P, Riemann JF, Rodel C, Sauer R, Sauerbruch T, Schmitt W, Schmoll HJ, Seufferlein T, Zeitz M, Selbmann HK: S3 guidelines for colorectal carcinoma: results of an evidence-based consensus conference on February 6/7, 2004 and June 8/9, 2007 (for the topics IV, VI and VII). Z Gastroenterol. 2010, 48 (1): 65-136. 10.1055/s-0028-1109936.CrossRefPubMed

13.

Schmiegel W, Reinacher-Schick A, Arnold D, Graeven U, Heinemann V, Porschen R, Riemann J, Rodel C, Sauer R, Wieser M, Schmitt W, Schmoll HJ, Seufferlein T, Kopp I, Pox C: [Update S3-guideline "colorectal cancer" 2008]. Z Gastroenterol. 2008, 46 (8): 799-840. 10.1055/s-2008-1027726.CrossRefPubMed

14.

Peto R, Peto J: Asymptotically Efficient Rank Invariant Test Procedures. Journal of the Royal Statistical Society. Series A (General). 1972, 135 (2): 185-207. 10.2307/2344317.CrossRef

15.

Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J, Smith PG: Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br J Cancer. 1977, 35 (1): 1-39. 10.1038/bjc.1977.1.CrossRefPubMedPubMedCentral

16.

Prentice RL: Linear rank tests with right censored data. Biometrika. 1978, 65 (1): 167-179. 10.1093/biomet/65.1.167.CrossRef

17.

Lan G, Demets D: Discrete sequential boundaries for clinical trials. Biometrika. 1983, 70 (3): 659-663.CrossRef

18.

O'Brien PC, Fleming TR: A multiple testing procedure for clinical trials. Biometrics. 1979, 35 (3): 549-56. 10.2307/2530245.CrossRefPubMed

19.

Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, Shimma N, Umeda I, Ishitsuka H: Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer. 1998, 34 (8): 1274-81. 10.1016/S0959-8049(98)00058-6.CrossRefPubMed

20.

Reigner B, Blesch K, Weidekamm E: Clinical pharmacokinetics of capecitabine. Clin Pharmacokinet. 2001, 40 (2): 85-104. 10.2165/00003088-200140020-00002.CrossRefPubMed

21.

Kweekel D, Guchelaar HJ, Gelderblom H: Clinical and pharmacogenetic factors associated with irinotecan toxicity. Cancer Treat Rev. 2008, 34 (7): 656-69. 10.1016/j.ctrv.2008.05.002.CrossRefPubMed

22.

Ferrara N, Hillan KJ, Gerber HP, Novotny W: Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 2004, 3 (5): 391-400. 10.1038/nrd1381.CrossRefPubMed

23.

Shibuya M: Angiogenesis regulated by VEGF and its receptors and its clinical application. Rinsho Ketsueki. 2009, 50 (5): 404-12.PubMed

24.

Seymour MT, Maughan TS, Ledermann JA, Topham C, James R, Gwyther SJ, Smith DB, Shepherd S, Maraveyas A, Ferry DR, Meade AM, Thompson L, Griffiths GO, Parmar MK, Stephens RJ: Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet. 2007, 370 (9582): 143-52. 10.1016/S0140-6736(07)61087-3.CrossRefPubMed

25.

Bouche O, Castaing M, Etienne PL, Texereau P, Auby D, Bedenne L, Rougier P, Gargot D, Gasmi M, Ducreux M: Randomized strategical trial of chemotherapy in metastatic colorectal cancer (FFCD 2000-05): Preliminary results. ASCO Meeting Abstracts. 2007, 25 (18_suppl): 4069-

26.

Kopetz S, Chang GJ, Overman MJ, Eng C, Sargent DJ, Larson DW, Grothey A, Vauthey JN, Nagorney DM, McWilliams RR: Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol. 2009, 27 (22): 3677-83. 10.1200/JCO.2008.20.5278.CrossRefPubMedPubMedCentral

27.

Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzen F, Cassidy J: Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008, 26 (12): 2013-9. 10.1200/JCO.2007.14.9930.CrossRefPubMed

28.

de Gramont A, Buyse M, Abrahantes JC, Burzykowski T, Quinaux E, Cervantes A, Figer A, Lledo G, Flesch M, Mineur L, Carola E, Etienne PL, Rivera F, Chirivella I, Perez-Staub N, Louvet C, Andre T, Tabah-Fisch I, Tournigand C: Reintroduction of oxaliplatin is associated with improved survival in advanced colorectal cancer. J Clin Oncol. 2007, 25 (22): 3224-9. 10.1200/JCO.2006.10.4380.CrossRefPubMed

29.

Allegra C, Blanke C, Buyse M, Goldberg R, Grothey A, Meropol NJ, Saltz L, Venook A, Yothers G, Sargent D: End points in advanced colon cancer clinical trials: a review and proposal. J Clin Oncol. 2007, 25 (24): 3572-5. 10.1200/JCO.2007.12.1368.CrossRefPubMed

The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/11/367/prepub

Title: A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: The AIO KRK 0110 Trial/ML22011 Trial
Authors: Clemens Giessen
Ludwig Fischer von Weikersthal
Axel Hinke
Sebastian Stintzing
Frank Kullmann
Ursula Vehling-Kaiser
Julia Mayerle
Markus Bangerter
Claudio Denzlinger
Markus Sieber
Christian Teschendorf
Jens Freiberg-Richter
Christoph Schulz
Dominik Paul Modest
Nicolas Moosmann
Philipp Aubele
Volker Heinemann
Publication date: 01-12-2011
Publisher: BioMed Central
Published in: BMC Cancer / Issue 1/2011
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/1471-2407-11-367

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods/Design

Conclusion

Trial Registration

Please log in to get access to this content

Other articles of this Issue 1/2011

Regulation of gene expression in ovarian cancer cells by luteinizing hormone receptor expression and activation

Differences in integrin expression and signaling within human breast cancer cells

Phase II study of induction chemotherapy with TPF followed by radioimmunotherapy with Cetuximab and intensity-modulated radiotherapy (IMRT) in combination with a carbon ion boost for locally advanced tumours of the oro-, hypopharynx and larynx - TPF-C-HIT

Latexin expression is downregulated in human gastric carcinomas and exhibits tumor suppressor potential

Sustained platelet-sparing effect of weekly low dose paclitaxel allows effective, tolerable delivery of extended dose dense weekly carboplatin in platinum resistant/refractory epithelial ovarian cancer

Primary leiomyosarcoma of the seminal vesicle: Case report and review of the literature

Keynote webinar | Spotlight on antibody–drug conjugates in cancer